强度治疗学报告了早期放射学和病理学结果，INT 230 6证明高药物吸收肿瘤坏死和免疫激活的证据

2025-09-10 19:49

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy ("SOC")
Safety looks favorable in Cohort A
Some INT230-6 patients begin to show localized skin irritation, and new patient enrollment has been paused to implement modifications to resolve the issue
Patients being treated with INT230-6 continue to show significant necrosis after two doses of INT230-6 and prior to the initiation of the SOC, as shown in the photos below of a single patient's breast tumor scans